Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Carl Graham and Katie Doores.
Carl Graham
Connection Strength
1.918
Katie Doores
  1. Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant. Immunity. 2021 06 08; 54(6):1276-1289.e6.
    View in: PubMed
    Score: 0.938
  2. Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans. Nat Microbiol. 2020 12; 5(12):1598-1607.
    View in: PubMed
    Score: 0.227
  3. The effect of methotrexate and targeted immunosuppression on humoral and cellular immune responses to the COVID-19 vaccine BNT162b2: a cohort study. Lancet Rheumatol. 2021 Sep; 3(9):e627-e637.
    View in: PubMed
    Score: 0.060
  4. Single dose of BNT162b2 mRNA vaccine against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) induces neutralising antibody and polyfunctional T-cell responses in patients with chronic myeloid leukaemia. Br J Haematol. 2021 09; 194(6):999-1006.
    View in: PubMed
    Score: 0.059
  5. SARS-CoV-2 can recruit a heme metabolite to evade antibody immunity. Sci Adv. 2021 05; 7(22).
    View in: PubMed
    Score: 0.059
  6. Single dose of BNT162b2 mRNA vaccine against SARS-CoV-2 induces high frequency of neutralising antibody and polyfunctional T-cell responses in patients with myeloproliferative neoplasms. Leukemia. 2021 12; 35(12):3573-3577.
    View in: PubMed
    Score: 0.059
  7. Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study. Lancet Oncol. 2021 06; 22(6):765-778.
    View in: PubMed
    Score: 0.059
  8. Clinical utility of targeted SARS-CoV-2 serology testing to aid the diagnosis and management of suspected missed, late or post-COVID-19 infection syndromes: Results from a pilot service implemented during the first pandemic wave. PLoS One. 2021; 16(4):e0249791.
    View in: PubMed
    Score: 0.059
  9. The effect of spike mutations on SARS-CoV-2 neutralization. Cell Rep. 2021 03 23; 34(12):108890.
    View in: PubMed
    Score: 0.058
  10. Author Correction: A dynamic COVID-19 immune signature includes associations with poor prognosis. Nat Med. 2020 Dec; 26(12):1951.
    View in: PubMed
    Score: 0.057
  11. Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England. J Infect. 2020 12; 81(6):931-936.
    View in: PubMed
    Score: 0.057
  12. Author Correction: A dynamic COVID-19 immune signature includes associations with poor prognosis. Nat Med. 2020 Oct; 26(10):1663.
    View in: PubMed
    Score: 0.057
  13. Comparative assessment of multiple COVID-19 serological technologies supports continued evaluation of point-of-care lateral flow assays in hospital and community healthcare settings. PLoS Pathog. 2020 09; 16(9):e1008817.
    View in: PubMed
    Score: 0.057
  14. Peripheral immunophenotypes in children with multisystem inflammatory syndrome associated with SARS-CoV-2 infection. Nat Med. 2020 11; 26(11):1701-1707.
    View in: PubMed
    Score: 0.056
  15. A dynamic COVID-19 immune signature includes associations with poor prognosis. Nat Med. 2020 10; 26(10):1623-1635.
    View in: PubMed
    Score: 0.056
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.